Core Viewpoint - MediPharm Labs Corp. is preparing for its Annual and Special Meeting of Shareholders on June 16, 2025, emphasizing the importance of shareholder support for its Board of Directors and strategic direction amidst a challenge from a dissident shareholder [1][2][6]. Financial Performance - In 2024, MediPharm reported a 27% year-over-year increase in net revenue and improved gross profit margin from 18% in 2023 to 31% [5]. - The company's Adjusted EBITDA loss narrowed by $8.3 million to $1.9 million in 2024 compared to the previous year, with expectations of reaching positive Adjusted EBITDA soon [5]. Strategic Developments - MediPharm has undergone a strategic revitalization, including the acquisition of VIVO Cannabis in March 2023, which has opened new international markets and contributed approximately $10 million in annual revenue from its Beacon brand in Australia [12][13]. - The company has streamlined operations, focusing on strategic business lines and reducing operating expenses by half through synergies from the VIVO acquisition [11][13]. Governance and Shareholder Engagement - The Board of Directors recommends shareholders vote using the GREEN proxy to support its nominees, highlighting concerns about the qualifications of dissident nominees from Apollo Technology Capital Corp. [2][6][16]. - MediPharm emphasizes its commitment to good governance practices, including an independent Chair and key committees, to enhance shareholder value [20][21]. Market Position and Future Outlook - MediPharm's product mix includes various cannabis products, with international sales exceeding 50% of revenues in recent quarters, positioning the company for growth in the medical cannabis sector [15]. - The company believes it has established a solid foundation for future growth and is committed to ongoing enhancements in governance and operational strategies [28][27].

As filed with the Securities and Exchange Commission on November 7, 2025 Registration No. 333-[●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 cbdMD, Inc. (Exact Name of Registrant As Specified In Its Charter) | North Carolina | 2833 | 47-3414576 | | --- | --- | --- | | (State Or Other Jurisdiction Of Incorporation Or Organization) | (Primary Standard Industrial | (I.R.S. Employer | | | Classification Code Number) | ...

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Data and Key Metrics Changes - Canopy Growth reported a net revenue increase of 30% year-over-year in the Canadian adult-use cannabis business for Q2, driven by strong demand for Claybourne-infused pre-rolls and new all-in-one vapes [4][12] - The company's adjusted EBITDA loss narrowed to CAD 3 million compared to a loss of CAD 6 million a year ago, reflecting improved margins and lower SG&A expenses [11][16] - Cash and cash equivalents stood at CAD 298 million as of September 30, 2025, exceeding debt balances by CAD 70 million [11] Business Line Data and Key Metrics Changes - Canadian adult-use cannabis revenue increased by 30% year-over-year, while the Canadian medical cannabis business grew by 17% year-over-year [12][6] - International cannabis sales declined by 39% year-over-year due to supply challenges and quality issues [12][7] - Storz & Bickel segment net revenue was CAD 16 million, up 5% sequentially but down 10% year-over-year [14] Market Data and Key Metrics Changes - Distribution among Alberta independent retailers increased by 20% year-over-year, reflecting stronger relationships with retail partners [5] - Patient registrations in the Canadian medical cannabis segment grew by 20% year-over-year, indicating a robust demand for medical products [6] Company Strategy and Development Direction - The company is focused on improving supply chain execution in international markets, particularly in Europe, to stabilize operations and drive future profitability [7][18] - Canopy Growth aims to enhance cultivation standards and product quality to meet consumer expectations and expand its market presence [6][10] - The company is committed to maintaining a disciplined approach to cost management while pursuing growth opportunities in both domestic and international markets [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with international performance but remains committed to improving supply chain execution and product quality [7][10] - The company anticipates continued growth in the Canadian adult-use and medical cannabis markets, supported by a robust innovation pipeline [17][19] - Management is closely monitoring proposed changes to medical cannabis reimbursement for veterans, which could impact access and quality of care [9][17] Other Important Information - The SG&A savings program has delivered over CAD 21 million in annualized savings, exceeding initial targets [8][15] - The company has no significant debt maturities prior to September 2027, providing financial flexibility [11] Q&A Session Summary Question: What changes are needed to reopen the pipeline for international markets? - Management is retooling the supply chain to satisfy European demand from Canadian GMP facilities without increasing costs [22][23] Question: What is the strategy regarding the ATM usage in Q2? - The company is continuously evaluating capital requirements and funding strategies to ensure an optimal capital structure [26][27] Question: Are there plans to increase vertical integration for international supply? - Management is confident in their capacity to supply from Canadian facilities and is currently retooling the route to market [30] Question: What is the timeline for achieving positive EBITDA? - Management is focused on controlling costs and improving adjusted EBITDA performance but refrained from providing specific timelines [31][32] Question: How is the company addressing capacity needs for growth? - Management believes current facilities can meet demand with limited investment focused on improving yield and quality [35][37] Question: What are the capital allocation priorities given the strong cash position? - The company is evaluating potential investment opportunities while maintaining resilience and stability in operations [39]

Core Insights - Tilray Brands (TLRY) shares have surged 94.5% over the past three months, significantly outperforming the industry which saw a 2.5% decline [1][9] - The stock's rise is attributed to optimism regarding potential federal regulations for hemp-derived products and indications of relaxed marijuana restrictions by President Donald Trump [2][9] - The company reported record first-quarter net revenues of $210 million, contributing to a strengthened balance sheet [2][9] Financial Performance - In the first quarter of fiscal 2026, Tilray Brands achieved a net income of $1.5 million, a significant turnaround from a net loss of $34.7 million in the same period last year [7][9] - Adjusted net income improved to $3.9 million from an adjusted net loss of $6 million year-over-year, driven by lower selling, general and administrative expenses and reduced amortization [7][9] Global Expansion - Tilray Medical is expanding its global footprint, establishing Solana Life Group in Panama to cultivate and distribute medical cannabis [4][9] - The company launched five new cannabis flower products in Germany and entered a strategic partnership with Italy's Molteni to enhance the availability of medical cannabis extracts [5][9] - In Australia, Tilray introduced its first medical cannabis edible, Good Supply Pastilles, emphasizing innovation in patient-focused treatment solutions [6][9] Competitive Landscape - Tilray Brands operates in a competitive market, facing challenges from peers like Village Farms International and Curaleaf Holdings, both pursuing international expansion and cost optimization [10] - As Tilray gains traction in international markets, competitive responses from these companies may intensify [10] Market Estimates and Challenges - The Zacks Consensus Estimate for fiscal 2026 sales indicates a year-over-year improvement of 6.8%, while loss per share is expected to deteriorate by 600% year-over-year [11] - The company faces challenges from price compression and regulatory issues in Canada, including high excise taxes and limited retail channels for cannabis beverages [12][14] - In Europe, growth is hindered by permit delays in Portugal and quota restrictions in Germany, along with currency volatility impacting performance [13][14] Valuation - Tilray shares are currently trading at a forward one-year price-to-sales (P/S) ratio of 1.52X, which is a discount compared to the industry average of 3.16X [15]

Core Points - POSaBIT Systems Corporation will host a conference call on November 12, 2025, at 4:30 PM ET to discuss its third-quarter financial results for the period ending September 30, 2025 [1] - The company is inviting investor questions to be submitted by 12:00 PM ET on the same day, which will be addressed by the CEO during the call [2] Conference Call Information - Date and Time: November 12, 2025, at 4:30 PM ET [3] - Toll-Free Number: 888-506-0062; International Number: 973-528-0011; Participant Access Code: 195719 [3] - Webcast URL for live event: https://www.webcaster5.com/Webcast/Page/2708/53211 [3] - Replay Information: Available approximately 1 hour after the live event, with a toll-free number for replay [3] Company Overview - POSaBIT is a leading provider of payments infrastructure specifically for the cannabis industry, offering a cashless payment solution for cannabis retailers [7] - The company focuses on developing advanced financial services and transaction methods to address the challenges of a cash-only industry [7]

Core Insights - C21 Investments Inc. will release its financial results for the second quarter ended September 30, 2025, on November 11, 2025, before market open [2]. Company Overview - C21 Investments Inc. is a vertically integrated cannabis company that cultivates, processes, and distributes quality cannabis consumer products in the United States [2]. - The company focuses on value creation through disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets [2]. - C21 owns Silver State Relief and Silver State Cultivation in Nevada, along with legacy Oregon brands such as Phantom Farms, Hood Oil, and Eco Firma Farms [2]. - These brands produce and distribute a wide range of THC and CBD products, including cannabis flowers, pre-rolls, cannabis oil, vaporizer cartridges, and edibles [2].

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $42.2 million, down 9% year-over-year, but in line with expectations, reflecting continued softness across core markets [12] - Average monthly revenue per paying client decreased by 12% year-over-year to $2,693, primarily due to overall revenue softness and a shift towards newer clients with lower spend levels [13] - Net income for the quarter was $3.6 million, with adjusted EBITDA of $7.6 million, demonstrating profitability amid a softer revenue environment [14] - Cash at the end of the quarter was $62.6 million, up 39% year-over-year, marking the ninth consecutive quarter of positive cash generation [14] Business Line Data and Key Metrics Changes - Revenue across all product categories declined year-over-year, with the majority of the decrease driven by featured and deal listings, which are typically the first areas clients scale back when budgets tighten [12] - Average monthly paying clients increased by 2% year-over-year to 5,221, reflecting continued client acquisition in developing markets, partially offset by churn in more mature states [12] Market Data and Key Metrics Changes - Average retail flower prices in California are down roughly 9% year-over-year, and more than 20% in Michigan, indicating significant price and margin compression in key markets [5] - Michigan has introduced a wholesale excise tax of 24% on top of existing taxes, exacerbating the challenges faced by the cannabis industry [6] Company Strategy and Development Direction - The company is being increasingly selective in aligning with clients for long-term prospects, sometimes foregoing near-term revenue to improve future opportunities [7] - The company is focusing on developing its brand offerings to better align with the state of the industry and is prioritizing growth with multi-state operators (MSOs) [10] - The company aims to balance near-term execution with long-term opportunities, especially in anticipation of potential federal regulatory changes [10] Management's Comments on Operating Environment and Future Outlook - Management noted that the cannabis industry is facing significant regulatory challenges and market pressures, which may lead to continued industry consolidation [6] - Despite the challenges, management believes that underlying demand and consumer adoption trends remain strong, presenting opportunities for the company to shape the legal cannabis economy [11] - The company expects revenue for Q4 2025 to be between $41 million and $43 million, reflecting ongoing pressure in mature markets and planned investments in key initiatives [15] Other Important Information - The company operates with no debt, providing flexibility to navigate near-term market volatility while investing in strategic initiatives [14] - The company has a strong focus on expense discipline and operational efficiency, which has allowed it to remain profitable despite revenue challenges [14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Group 1 - The article highlights the strong performance of the analyst team, achieving an annualized return of almost 40% over the past decade with a long-only model portfolio return of over 23 times [1] - The focus is on providing income-focused picks for investors who prefer lower-risk firms with steady dividend payouts [1] Group 2 - The analyst has previously covered Aurora Cannabis Inc., indicating that this article serves as an update to earlier coverage [2] - The analyst has a historical focus on tech stocks but has expanded coverage to include the offshore drilling, supply industry, and shipping industry [3]

Group 1 - The analyst team has a proven track record of outperforming across all market conditions, achieving an annualized return of almost 40% over the past decade with a long-only model portfolio return of over 23x [1] - The focus includes income-oriented picks for investors preferring lower-risk firms with steady dividend payouts [1] - The research covers sectors such as energy, shipping, and offshore markets, indicating a broad scope of industry analysis [1] Group 2 - Aurora Cannabis Inc. is mentioned as a company previously covered, indicating ongoing interest and updates regarding its performance [2] - The analyst has expanded coverage to include offshore drilling, supply industry, and shipping, alongside a focus on the fuel cell industry [3] - The analyst has a background in auditing and trading, providing a diverse perspective on market movements and industry trends [3]